Website Banner   Desktop (3)

Five biotech innovators transforming mental health care

Posted on 14 May 2021 by Jacob Stafford-Wright

Website Banner   Desktop (3)

Five biotech innovators transforming mental health care

Posted on 14 May 2021 by Jacob Stafford-Wright


A mental health crisis has sparked innovation from major names within the biotechnology industry, with several firms hitting the spotlight in the last few years as a result of cutting-edge research, contemporary methodology or innovative product application in the treatment of anxiety, depression, PTSD and other cognitive disorders.

A particularly flourishing branch of mental health treatment can be seen in the use of psychedelics, where early research and application is garnering promising results, the likes of which haven’t gone unnoticed by major life science firms and investors alike.

But the mental health market is massive, and it’s not only psychedelics drawing attention to the space. Wearables, diagnostics, artificial intelligence, and digital engagement platforms are all being explored with the intent to provide better outcomes for mental health patients. Here are five firms making waves in the sector.

Lobe Sciences

Lobe Sciences focus on the clinical development of medical devices and psychedelic medicines to treat neurological disorders and brain traumas, and have an impressive and diverse portfolio of 5 provisional patents – 3 for treatments that use psychedelic compounds and a further 2 for medical devices.

Last month the firm announced a joint venture with Virtual Psychedelics Incorporated to develop digital therapeutic pods, set to be powered by a custom tech stack that combines display technology and biomonitoring to create a multi-sensory virtual experience.

"We believe this technology will be able to assist those suffering from depression, PTSD and other mental health issues. The KrysalisTM Pod is being designed as a therapeutic system capable of delivering an easy, immersive media experience, while simultaneously collecting critical biometric data in a safe and monitored environment."

Sage Therapeutics

Postpartum (or postnatal) depression is believed to be the most common complication of childbirth, affecting roughly 1 in 7 people after delivering a child. Typically though, new mothers have had access to no treatments specifically designed to target the condition. Instead, they are prescribed antidepressant drugs that are approved for the general population, so it's not clear if they're safe or effective, and they don't always work.

Sage Therapeutics set out to change this, and their treatment ZULRESSO became the first FDA-approved treatment for the condition back in 2019, and remains the only treatment specifically indicated for postpartum depression (PPD). In studies, mothers undergoing the treatment after childbirth experienced a reduction in symptoms of PPD in just 2.5 days, with maintained results in mood measured at the 30-day mark too.

This year the company plan to launch three new trials to test an additional product, SAGE-217, against the treatment of the condition.


Commonly prescribed treatments for clinical depression often come with the risk of adverse side effects, so many patients opt against traditional antidepressant drugs. Neuronetics provide an alternative with their product NeuroStar, a non-drug, non-invasive treatment that uses magnetic pulses to stimulate areas of the brain that are underactive in those suffering from depression.

An open-label trial into the product saw almost half of participants experience significant improvement in depression symptoms. Some also experienced an improvement in their anxiety, appetite, and energy levels.

The market-leading medtech firm has delivered over 2.8 million treatments to patients suffering from depression since their product hit the market in 2008, and last year they were named as a Top 10 Neurology Device Provider by MedTech Outlook Magazine.

atai Life Sciences

Global biotech atai Life Sciences have only been in the mental health space since 2018, but are involved in almost a dozen ongoing efforts analysing the effect of various compounds on depression, anxiety, addiction, and other mental health disorders.

Many of the therapies under research by atai make use of psychedelic compounds, but in the last year the company have also invested heavily in the digital health space, acquiring a majority stake in digital therapeutics firm Psyber and launching their own digital platform, IntroSpect.

The company hope to utilise the flexibility and power of technology to meet the need of patients on their own terms, and use digital biomarkers to make mental health treatments more refined, effective and individualised.

Pear Therapeutics

In the last year, Pear Therapeutics has announced a variety of partnerships with key players in the fields of wearables, diagnostics and AI and have raised $80m to develop their digital therapeutics that aim to support the treatment of a variety of cognitive disorders.

They hope to redefine medicine by discovering, developing and delivering software-based therapeutics to provide better outcomes for sufferers of depression, bipolar disorder, schizophrenia and substance use disorder. Pear hit the news this year as the Ohio Department of Mental Health & Addiction Services became the third state regulator to fund their digital therapeutics to tackle behavioural health and addiction recovery.